The Ohio State University Comprehensive Cancer Center (OSUCCC) is currently in its 35th year as an NCI designated CCC and is now requesting continued federal support for the next five years. Dr. Caligiuri currently continues in his seventh year as the OSUCCC Director and has since been named CEO of OSU's freestanding James Cancer Hospital. The overall goal remains to reduce cancer morbidity and mortality through continued basic, translational and clinical research. The 239 OSUCCC full, associate or introductory members are currently served by 18 shared resources and are distributed among the our six Research Programs which remain unchanged: Cancer Control, Experimental Therapeutics, Innate Immunity, Molecular Biology and Cancer Genetics, Molecular Carcinogenesis and Chemoprevention, and Viral Oncology. Since the last competitive renewal, the OSUCCC has shown significant growth as demonstrated by: 1) the recruitment of 159 faculty focused in basic, translational and clinical cancer research and medicine;2) more than a 80% increase in patient accrual to investigator-initiated trials;3) the addition of 5 new shared resources at an institutional investment of over $4.2 million;4) a 96% increase in total NCI funding despite a period of relatively flat federal funding;5) an 85% increase in publications, 51% of which were collaborative (i.e., inter-, intra-programmatic, or both);5) discovery, preclinical development and administration of two new anti-cancer agents into man, along with additional important advances in basic and clinical cancer research. The OSUCCC has also seen tremendous growth in institutional commitment since 2004 as demonstrated by 1) a ten-fold increase in annual financial support (now approximately $50 million) for the OSUCCC under the control of the Director;2) an additional $7.0 million of cash annually from OSU for research and infrastructure expansion;3) a formal direct reporting relationship to the Executive Vice President and Provost with complete oversight of the University-wide cancer funding initiatives, opportunities and cancer grant submissions;4) A seat on the University President's cabinet providing representation of the CCC at the highest level of the University;5) a six-fold increase in space currently under the sole control of the Director, including new additional dry and wet laboratory and office space for recruitment of additional faculty;6) a written commitment and approval by the OSU Board of Trustees for the expansion of the Cancer Program facilities that will more than double the current square footage under control of the OSUCCC Director in the next five years at a cost of approximately $800 million. With these new resource commitments in place, the OSUCCC is poised for continued significant growth and expansion in the next 5 years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-38
Application #
8601791
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-09-12
Project End
2015-11-30
Budget Start
2014-03-13
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$4,124,073
Indirect Cost
$1,419,763
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Salem, Galena; Ruppert, Amy S; Elder, Patrick et al. (2015) Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. Leuk Lymphoma 56:1058-65
Niederwieser, C; Kohlschmidt, J; Volinia, S et al. (2015) Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia 29:567-75
Billingsley, Caroline C; Cohn, David E; Mutch, David G et al. (2015) Polymerase ? (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. Cancer 121:386-94
Krok-Schoen, Jessica L; Kurta, Michelle L; Weier, Rory C et al. (2015) Clinic type and patient characteristics affecting time to resolution after an abnormal cancer-screening exam. Cancer Epidemiol Biomarkers Prev 24:162-8
Biddle, Martha J; Lennie, Terry A; Bricker, Gregory V et al. (2015) Lycopene dietary intervention: a pilot study in patients with heart failure. J Cardiovasc Nurs 30:205-12
Jin, Ming; Roth, Rachel; Rock, Jonathan B et al. (2015) The impact of tumor deposits on colonic adenocarcinoma AJCC TNM staging and outcome. Am J Surg Pathol 39:109-15
Llanos, Adana A; Pennell, Michael L; Young, Gregory S et al. (2015) No association between colorectal cancer worry and screening uptake in Appalachian Ohio. J Public Health (Oxf) 37:322-7
Nguyen, Huyen T; Jia, Guang; Shah, Zarine K et al. (2015) Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrast-enhanced (DCE)-MRI pharmacokinetic parameters. J Magn Reson Imaging 41:1374-82
Berman-Booty, Lisa D; Thomas-Ahner, Jennifer M; Bolon, Brad et al. (2015) Extra-prostatic transgene-associated neoplastic lesions in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice. Toxicol Pathol 43:186-97
Pant, Shubham; Martin, Ludmila K; Geyer, Susan et al. (2014) Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer 120:1780-6

Showing the most recent 10 out of 1178 publications